Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals
© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases..
BACKGROUND AND AIMS: Hepatic ischemia-reperfusion injury (IRI) is the leading cause of early posttransplantation organ failure as mitochondrial respiration and ATP production are affected. A shortage of donors has extended liver donor criteria, including aged or steatotic livers, which are more susceptible to IRI. Given the lack of an effective treatment and the extensive transplantation waitlist, we aimed at characterizing the effects of an accelerated mitochondrial activity by silencing methylation-controlled J protein (MCJ) in three preclinical models of IRI and liver regeneration, focusing on metabolically compromised animal models.
APPROACH AND RESULTS: Wild-type (WT), MCJ knockout (KO), and Mcj silenced WT mice were subjected to 70% partial hepatectomy (Phx), prolonged IRI, and 70% Phx with IRI. Old and young mice with metabolic syndrome were also subjected to these procedures. Expression of MCJ, an endogenous negative regulator of mitochondrial respiration, increases in preclinical models of Phx with or without vascular occlusion and in donor livers. Mice lacking MCJ initiate liver regeneration 12 h faster than WT and show reduced ischemic injury and increased survival. MCJ knockdown enables a mitochondrial adaptation that restores the bioenergetic supply for enhanced regeneration and prevents cell death after IRI. Mechanistically, increased ATP secretion facilitates the early activation of Kupffer cells and production of TNF, IL-6, and heparin-binding EGF, accelerating the priming phase and the progression through G1 /S transition during liver regeneration. Therapeutic silencing of MCJ in 15-month-old mice and in mice fed a high-fat/high-fructose diet for 12 weeks improves mitochondrial respiration, reduces steatosis, and overcomes regenerative limitations.
CONCLUSIONS: Boosting mitochondrial activity by silencing MCJ could pave the way for a protective approach after major liver resection or IRI, especially in metabolically compromised, IRI-susceptible organs.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Hepatology (Baltimore, Md.) - 75(2022), 3 vom: 10. März, Seite 550-566 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 03.03.2022 Date Revised 31.07.2022 published: Print-Electronic ErratumIn: Hepatology. 2022 Aug;76(2):532. - PMID 35451511 Citation Status MEDLINE |
|---|
| doi: |
10.1002/hep.32149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330526995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330526995 | ||
| 003 | DE-627 | ||
| 005 | 20231225211457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hep.32149 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330526995 | ||
| 035 | |a (NLM)34510498 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goikoetxea-Usandizaga, Naroa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mitochondrial bioenergetics boost macrophage activation, promoting liver regeneration in metabolically compromised animals |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2022 | ||
| 500 | |a Date Revised 31.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Hepatology. 2022 Aug;76(2):532. - PMID 35451511 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. | ||
| 520 | |a BACKGROUND AND AIMS: Hepatic ischemia-reperfusion injury (IRI) is the leading cause of early posttransplantation organ failure as mitochondrial respiration and ATP production are affected. A shortage of donors has extended liver donor criteria, including aged or steatotic livers, which are more susceptible to IRI. Given the lack of an effective treatment and the extensive transplantation waitlist, we aimed at characterizing the effects of an accelerated mitochondrial activity by silencing methylation-controlled J protein (MCJ) in three preclinical models of IRI and liver regeneration, focusing on metabolically compromised animal models | ||
| 520 | |a APPROACH AND RESULTS: Wild-type (WT), MCJ knockout (KO), and Mcj silenced WT mice were subjected to 70% partial hepatectomy (Phx), prolonged IRI, and 70% Phx with IRI. Old and young mice with metabolic syndrome were also subjected to these procedures. Expression of MCJ, an endogenous negative regulator of mitochondrial respiration, increases in preclinical models of Phx with or without vascular occlusion and in donor livers. Mice lacking MCJ initiate liver regeneration 12 h faster than WT and show reduced ischemic injury and increased survival. MCJ knockdown enables a mitochondrial adaptation that restores the bioenergetic supply for enhanced regeneration and prevents cell death after IRI. Mechanistically, increased ATP secretion facilitates the early activation of Kupffer cells and production of TNF, IL-6, and heparin-binding EGF, accelerating the priming phase and the progression through G1 /S transition during liver regeneration. Therapeutic silencing of MCJ in 15-month-old mice and in mice fed a high-fat/high-fructose diet for 12 weeks improves mitochondrial respiration, reduces steatosis, and overcomes regenerative limitations | ||
| 520 | |a CONCLUSIONS: Boosting mitochondrial activity by silencing MCJ could pave the way for a protective approach after major liver resection or IRI, especially in metabolically compromised, IRI-susceptible organs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Mcj protein, mouse |2 NLM | |
| 650 | 7 | |a Mitochondrial Proteins |2 NLM | |
| 650 | 7 | |a Molecular Chaperones |2 NLM | |
| 700 | 1 | |a Serrano-Maciá, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Delgado, Teresa C |e verfasserin |4 aut | |
| 700 | 1 | |a Simón, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández Ramos, David |e verfasserin |4 aut | |
| 700 | 1 | |a Barriales, Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Cornide, Maria E |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez, Mónica |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Redondo, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Lachiondo-Ortega, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Agudo, Rubén |e verfasserin |4 aut | |
| 700 | 1 | |a Bizkarguenaga, Maider |e verfasserin |4 aut | |
| 700 | 1 | |a Zalamea, Juan Diego |e verfasserin |4 aut | |
| 700 | 1 | |a Pasco, Samuel T |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero-Díaz, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Alfano, Benedetta |e verfasserin |4 aut | |
| 700 | 1 | |a Bravo, Miren |e verfasserin |4 aut | |
| 700 | 1 | |a González-Recio, Irene |e verfasserin |4 aut | |
| 700 | 1 | |a Mercado-Gómez, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Gil-Pitarch, Clàudia |e verfasserin |4 aut | |
| 700 | 1 | |a Mabe, Jon |e verfasserin |4 aut | |
| 700 | 1 | |a Gracia-Sancho, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Abecia, Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Óscar |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Sanz, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a Abrescia, Nicola G A |e verfasserin |4 aut | |
| 700 | 1 | |a Sabio, Guadalupe |e verfasserin |4 aut | |
| 700 | 1 | |a Rincón, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Anguita, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Miñambres, Eduardo |e verfasserin |4 aut | |
| 700 | 1 | |a Martín, César |e verfasserin |4 aut | |
| 700 | 1 | |a Berenguer, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Fabregat, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Casado, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Peralta, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Varela-Rey, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Chantar, María Luz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology (Baltimore, Md.) |d 1983 |g 75(2022), 3 vom: 10. März, Seite 550-566 |w (DE-627)NLM012603902 |x 1527-3350 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:3 |g day:10 |g month:03 |g pages:550-566 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hep.32149 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 3 |b 10 |c 03 |h 550-566 | ||